comparing glp-1 agonists for Weight Loss: A Side-by-Side Comparison Compare GLP-1 Options | Ozempic

2024;11:e2405987

Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER

Common strategies for extending the duration of GLP-1 RAs include: Amino Acid Sequence Optimization : Reducing rapid degradation by DPP-4 enzymes to extend the drug's half-life

Meta-analysis of 34 trials showed that among GLP-1 receptor agonists, once-daily exenatide has the lowest risk of vomiting, while albiglutide had the highest risk for diarrhea

Consistent with these findings, the BWMR analysis in the validation cohort (FinnGen Consortium) showed suggestive evidence of a protective effect of elevated GLP-1R gene expression against DR risk (OR = 0.70, 95% CI: 0.510.96, P = 0.029)

"However, another recent epidemiologic study also confirmed an increase in risk." BMI IS WRONG WAY TO MEASURE OBESITY, RESEARCHERS SAY HERES WHAT THEY RECOMMEND INSTEAD Al-Aly called for large, controlled studies including people who take the drug and a control group of people who are not using the drug to evaluate the long-term health effects of these medications, including eye problems